- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05094765
Fecal Microbiota Transplant (FMT) Capsule for Improving the Efficacy of GI-aGVHD
Evaluating Safety and Efficacy of GI-XBI-302 in Patients With Glucocorticoid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation
Study Overview
Study Type
Enrollment (Anticipated)
Phase
- Early Phase 1
Contacts and Locations
Study Contact
- Name: yanli zhao
- Phone Number: 0316-3306412
- Email: 13121053519@163.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
1. GVHD within 100 days after allogeneic hematopoietic stem cell transplantation (allo HSCT);
2. Age 18 - 65 years old, regardless of gender;
3. Patients with grade 3 or 4 gastrointestinal involvement (aGVHD) according to the International Alliance (Magic) classification standard;
4. Patients with glucocorticoid resistant GI aGVHD are diagnosed. According to the expert consensus of Chinese allogeneic hematopoietic stem cell transplantation for the treatment of hematological diseases (III) - acute graft-versus-host disease (2020 Edition), the definition of glucocorticoid resistant acute GVHD is Thomas' hematopoietic cell transplantation: stem cell transplantation (5th Edition) Glucocorticoid resistance was defined as PD at 3 days, NR at 7 days or Cr not reached at 14 days after first-line treatment.
5. ECoG 3 points or less;
6. Stop prophylactic antibiotics at least 12 hours before FMT treatment;
7. Be able and willing to sign informed consent;
8. Patients who are capable of swallowing capsules and can complete the study;
Exclusion Criteria:
1. There are active but uncontrolled infections, except GVHD complicated with infectious diarrhea;
2. Gastrointestinal perforation, active gastrointestinal bleeding, small intestinal obstruction, toxic megacolon or other serious gastrointestinal diseases not caused by GVHD;
3. Have a history of severe allergic reaction; Or known to be allergic to any ingredient of intestinal bacteria capsule xbi-302;
4. Any serious disease that can increase the risk of patients participating in the study;
5. Female subjects with positive pregnancy test and lactation, or female subjects of childbearing age who refuse to take contraceptive measures during the study;
6. According to the judgment of the researcher, the patients with high dynamic diarrhea can not stay in the intestine for enough time to dissolve the capsule.
7. HIV, HBV, HCV and syphilis are positive;
8. After colectomy;
9. Participate in other intervention clinical studies within 4 weeks before the screening period;
10. The expected survival time is less than 12 weeks;
11. The basic body function test is inferior to the following standards: total neutrophils (neu) < 0.5 (x109 / L), platelet count (PLT) < 30 (x109 / L), serum creatinine (CR) > 1.5 times the maximum normal value (ULN), albumin (ALB) < 25g / L;
12. There is any situation that the researcher thinks is not suitable for inclusion (any history of medical history, treatment history or abnormal test data that may confuse the results of this study, interfere with the subject's whole participation in the study, or harm the interests of the subject).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: FMT
60 capsules per day for 2 day
|
Fecal Microbiota Transplantation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ORR
Time Frame: Day 28
|
assessed by Overall Response Rate (ORR) at Day 28
|
Day 28
|
AE
Time Frame: Day 28
|
assessed all related a grade 3 or above adverse event (AE) at Day 28
|
Day 28
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AE
Time Frame: up to 25 weeks
|
assessed all related adverse event (AE)
|
up to 25 weeks
|
Shannon index
Time Frame: up to 25 weeks
|
changes of Shannon index
|
up to 25 weeks
|
colonization bacteria analysis
Time Frame: up to 25 weeks
|
the number and relative abundance of bacteria that originally existed only in the capsule but could still be detected in the stool samples of subjects
|
up to 25 weeks
|
PFS
Time Frame: up to 25 weeks
|
Kaplan-Meier Curve
|
up to 25 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Metabonomics
Time Frame: up to 25 weeks
|
The changes of calprotectin, Is, SCFA and bile acid were compared
|
up to 25 weeks
|
biomarkers
Time Frame: up to 25 weeks
|
The changes of IL-6、IL-8、sTNFR1、sST2、Reg3a、Elafin were compared
|
up to 25 weeks
|
Immunohistochemistry
Time Frame: up to 25 weeks
|
The phenotypes and subsets of CD4 and CD8 positive T cells, B cells, NK cells and monocytes were compared
|
up to 25 weeks
|
Proportion of patients
Time Frame: up to 25 weeks
|
Proportion of patients with hormone dosage ≤ 20mg / day equivalent to equivalent converted dose of prednisolone
|
up to 25 weeks
|
The proportion of patients
Time Frame: up to 25 weeks
|
who stopped antibiotics was compared.
|
up to 25 weeks
|
Percentage of patients
Time Frame: up to 25 weeks
|
Percentage of patients who died due to GVHD
|
up to 25 weeks
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- XCT4843002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on GVHD
-
Shanghai Jiao Tong University School of MedicineCompleted
-
MaaT PharmaRecruitingSteroid Refractory GVHD | Intestinal GVHDFrance
-
Mats RembergerThe Swedish Research CouncilRecruitingGVHD, AcuteSweden, Norway, Denmark
-
CSL BehringTerminated
-
Weill Medical College of Cornell UniversityTerminatedGlucocorticosteroid Refractory Acute GVHDUnited States
-
Fondazione Policlinico Universitario Agostino Gemelli...Recruiting
-
Nationwide Children's HospitalDaisy FoundationCompletedGVHD | Hematopoietic Stem Cell TransplantUnited States
-
daphne brockingtonUnknownChronic GVHD After HCT for Cancer or Immune DiseaseCanada
-
University of SalamancaRecruitingGVHD, Chronic | GVHD,AcuteSpain
-
Duke UniversityRecruiting
Clinical Trials on FMT
-
University of North Carolina, Chapel HillThe Broad Foundation; Crohn's and Colitis Foundation; OpenBiomeTerminated
-
University GhentUniversity Hospital, Ghent; Research Foundation Flanders; the Flanders Institute... and other collaboratorsCompleted
-
Fondazione Policlinico Universitario Agostino Gemelli...Recruiting
-
The University of Hong KongUnknownDevelopmental Coordination DisorderHong Kong
-
Fondazione Policlinico Universitario Agostino Gemelli...Not yet recruitingEnterobacteriaceae Infections | Multi-antibiotic ResistanceItaly
-
Universitaire Ziekenhuizen KU LeuvenFund for Scientific Research, Flanders, BelgiumUnknown
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingUlcerative Colitis | Clostridium DifficileItaly
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingEnterobacteriaceae Infections | Multi-antibiotic ResistanceItaly
-
Aleris-Hamlet Hospitaler KøbenhavnUniversity of Aarhus; Hvidovre University HospitalCompletedIrritable Bowel SyndromeDenmark
-
McMaster UniversitySt. Joseph's Healthcare Hamilton; Hamilton Health Sciences Corporation; Queen... and other collaboratorsCompletedClostridium Difficile InfectionCanada